Circulating tumor DNA may be an effective biomarker for stratifying patients with small cell lung cancer who would benefit from more stringent follow-ups and clinical trial participation.Patients who ...
Accent Therapeutics launched a Phase I/II clinical trial last year to begin testing a small molecule inhibitor of KIF18A in ovarian cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results